Document:

EX-10.69

 Exhibit 10.69 

AMENDED AND RESTATED EXECUTIVE EMPLOYMENT 

AGREEMENT BY AND BETWEEN 

HORIZON PHARMA, INC., HORIZON PHARMA USA, INC. AND 

GEOFF CURTIS 
 This Amended
and Restated Executive Employment Agreement (hereinafter referred to as the “Agreement”), is entered into by and between Horizon Pharma, Inc., a Delaware corporation, and its wholly owned subsidiary, Horizon Pharma USA, Inc.,
a Delaware corporation, each having a principal place of business at 150 S. Saunders Road, Lake Forest, IL 60045, (hereinafter referred to together as the “Company”) and Geoff Curtis (hereinafter referred as to the
“Executive”). The terms of this Agreement shall be effective commencing August 1, 2018 (the “Effective Date”). 

RECITALS 
 WHEREAS,
the Executive previously entered into an Executive Employment Agreement with the Company dated February 26, 2016 (the “Prior Agreement”). 

WHEREAS, the Company desires assurance of the continued association and services of the Executive in order to continue to retain the
Executive’s experience, skills, abilities, background and knowledge, and is willing to continue to engage the Executive’s services on the terms and conditions set forth in this Agreement; and 

WHEREAS, Executive desires to be in the continued employ of the Company, and is willing to accept such continued employment on the
terms and conditions set forth in this Agreement, which as of the Effective Date shall replace and supersede in its entirety the terms of the Prior Agreement. 

AGREEMENT 
  

	1.	 Employment. 

1.1 Term. The Executive originally commenced employment with the Company on April 1, 2015. The Company hereby agrees to
continue to employ the Executive, and the Executive hereby accepts continued employment by the Company, upon the terms and conditions set forth in this Agreement. Executive’s employment shall be governed under the terms set forth in this
Agreement beginning on the Effective Date and shall continue until it is terminated pursuant to Section 4 herein (hereinafter referred to as the “Term”). 

1.2 Title. From and after the Effective Date the Executive will have the title of executive vice president, corporate affairs
and chief communications officer (such position held by Executive during such period is hereinafter referred to as “EVP CCO” and Executive shall continue to serve in such other capacity or capacities commensurate with his
position as EVP CCO as the President and CEO of the Company may from time to time prescribe. 

 1.3 Duties. The Executive shall do and perform all services, acts or things
necessary or advisable to manage and conduct the business of the Company and shall have the authority and responsibilities which are generally associated with the position of EVP CCO including being responsible for the Company’s business units.
The Executive shall report to the President and CEO. 
 1.4 Policies and Practices. The employment relationship between the
parties shall be governed by this Agreement and the policies and practices established by the Company and the Board of Directors (hereinafter referred to as the “Board”). In the event that the terms of this Agreement differ
from or are in conflict with the Company’s policies or practices or the Company’s Employee Handbook, this Agreement shall control. 

1.5 Location. The Executive shall perform the services the Executive is required to perform pursuant to this Agreement in at the
Company’s U.S. Headquarters in Lake Forest Illinois. The Company may from time to time require the Executive to travel temporarily to other locations outside of Lake Forest, Illinois area in connection with the Company’s business. 

 

	2.	 Loyalty of Executive. 

2.1 Loyalty. During the Executive’s employment by the Company, the Executive shall devote the Executive’s business
energies, interest, abilities and productive time to the proper and efficient performance of Executive’s duties under this Agreement. Subject to the prior written consent of the President and CEO, the Executive is permitted to serve on the
board of directors of one other company, so long as the other company does not compete with the Company. 
 2.2 Exclusive
Employment. Except with the prior written consent of the Chief Executive Officer, Executive shall not, during the term of this Agreement, undertake or engage in any other employment, occupation or business enterprise, other than ones in which
Executive is a passive investor. The Company specifically agrees that the Executive may engage in any civic and not-for-profit board membership or activities (including,
but not limited to Executive role on the board of the Arthritis Foundation) so long as such activities do not materially interfere with the performance of his duties hereunder or present a conflict of interest with the Company. 

2.3 Agreement not to Participate in Company’s Competitors. During the Term of this Agreement, the Executive agrees not to
acquire, assume or participate in, directly or indirectly, any position, investment or interest known by Executive to be adverse or antagonistic to the Company, its business or prospects, financial or otherwise or in any company, person or entity
that is, directly or indirectly, in competition with the business of the Company or any of its affiliates. Notwithstanding the foregoing, Executive may invest and/or maintain investments in any public or private entity up to an amount of 2% of an
entity’s fully diluted shares and on a passive basis. 

	3.	 Compensation to Executive. 

3.1 Base Salary. The Company shall pay the Executive a base salary at the initial annualized rate of four hundred sixty thousand
dollars ($460,000.00) per year, subject to standard deductions and withholdings, or such higher rate as may be determined from time to time by the Board or the compensation committee thereof (hereinafter referred to as the “Base
Salary”) . Such Base Salary shall be paid in accordance with the Company’s standard payroll practice. Payments of salary installments shall be made no less frequently than once per month. Executive’s Base Salary will be
reviewed annually and Executive shall be eligible to receive a salary increase (but not decrease) annually in an amount to be determined by the Board or the compensation committee thereof in its sole and exclusive discretion. Once increased, the new
salary shall become the Base Salary for purposes of this Agreement and shall not be reduced without the Executive’s written consent. Any material reduction in the Base Salary of the Executive, without his written consent, may be deemed Good
Reason as set forth in and subject to Section 4.5.2 of this Agreement. 
 3.2 Discretionary Bonus. Provided the Executive
meets the conditions stated in this Section 3.2, the Executive shall be eligible for an annual discretionary bonus (hereinafter referred to as the “Bonus”) with a target amount of fifty percent (50%) of the
Executive’s Base Salary, subject to standard deductions and withholdings, based on the Board’s determination, in good faith, and based upon the Executive’s individual achievement and company performance objectives as set by the Board
or the compensation committee thereof, of whether the Executive has met such performance milestones as are established for the Executive by the Board or the compensation committee thereof, in good faith, in consultation with the Executive
(hereinafter referred to as the “Performance Milestones”) . The Performance Milestones will be based on certain factors including, but not limited to, the Executive’s performance and the Company’s financial
performance. The Executive’s Bonus target will be reviewed annually and may be adjusted by the Board or the compensation committee thereof in its discretion, provided however, that the Bonus target may only be materially reduced upon
Executive’s written consent. The Executive must be employed on the date the Bonus is awarded to be eligible for the Bonus, subject to the termination provisions thereof. The Bonus shall be paid during the calendar year following the performance
calendar year. 
 3.3 Prior Equity Grants. All Company equity awards previously granted to Executive shall continue in effect
from and following the Effective Date in accordance with their existing terms. Executive may be eligible to receive additional grants of Company equity awards in the sole discretion and subject to the approval of the Board. 

3.4 Legal Review. Upon the Executive’s submission of appropriate proof and verification of reasonable and customary legal
fees incurred by the Executive in obtaining legal advice associated with the review, preparation, approval, and execution of this Agreement, the Company shall pay for up to $10,000.00 of such legal fees subject to receipt of appropriate proof and
verification of such legal fees no later than sixty (60) days of receipt of an invoice for legal services from the Executive and/or his attorneys. 

 To be eligible for reimbursement, the invoice must be submitted no later than ninety (90) days after
the legal fees are incurred. 
 3.5 Changes to Compensation. The Executive’s compensation may be changed from time to
time by mutual agreement of the Executive and the Company. In the event that the Executive’s Base Salary is materially decreased without his written consent, said decrease will be Good Reason for the Executive to terminate the Agreement as set
forth in and subject to Section 4.5.2 of this Agreement. Without limitation, Executive shall be entitled to participate in the Company sponsored 401k and Deferred Compensation plans and other compensation/benefit plans in which Executive now
participates. 
 3.6 Taxes. All amounts paid under this Agreement to the Executive by the Company will be paid less applicable
tax withholdings and any other withholdings required by law or authorized by the Executive. 
 3.7 Benefits. The Executive
shall, in accordance with Company policy and the terms of the applicable plan documents, be eligible to participate in benefits under any executive benefit plan or arrangement which may be in effect from time to time and made available to the
Company’s executives or key management employees, provided, however, that the Executive shall be entitled to at least four (4) weeks of paid vacation annually. 

3.8 Expense Reimbursement. The Company shall reimburse the Executive for all reasonable and necessary out-of-pocket expenses incurred by Executive in the performance of his executive duties and responsibilities hereunder, including without limitation expenses incurred for all
of Executive’s travel and accommodations, subject to the Company’s normal policies and procedures, including without limitation, for expense verification and documentation (it being understood by the parties hereto that the
Executive’s duties hereunder will differ in scope and intensity from Company’s non -executive employees). 
  

	4.	 Termination. 

4.1 Termination by the Company. The Executive’s employment with the Company may be terminated only under the following
conditions: 
 4.1.1 Termination for Death or Disability. The Executive’s employment with the Company shall terminate
effective upon the date of the Executive’s death or “Complete Disability” (as defined in Section 4.5.1), provided, however, that this Section 4.1.1 shall in no way limit the Company’s obligations to
provide such reasonable accommodations to the Executive and/or his heirs as may be required by law. 
 4.1.2 Termination by the
Company For Cause. The Company may terminate the Executive’s employment under this Agreement for “Cause” (as defined in Section 4.5.3) by delivery of written notice to the Executive specifying the Cause or
Causes relied upon for such termination, provided that such notice is delivered within two 

 (2) months following the occurrence or discovery of any event or events constituting
“Cause”. Any notice of termination given pursuant to this Section 4.1.2 shall effect termination as of the date of the notice or such date as specified in the notice. The Executive shall have the right to appear before
the CEO before any termination for Cause becomes effective and binding upon the Executive. 
 4.1.3 Termination by the Company
Without Cause. The Company may terminate the Executive’s employment under this Agreement at any time and for any reason or no reason subject to the requirements set out in Section 4.4 of this Agreement. Such termination shall be
effective on the date the Executive is so informed or as otherwise specified by the Company, pursuant to notice requirements set forth in Section 6 of this Agreement. 

4.2 Termination By The Executive. The Executive may terminate his employment with the Company at any time and for any reason or
no reason, including, but not limited, to the following conditions: 
 4.2.1 Good Reason. The Executive may terminate his
employment under this Agreement for “Good Reason” (as defined below in Section 4.5.2) by delivery of written notice to the Company specifying the Good Reason(s) relied upon by the Executive for such termination in
accordance with the requirements of such section. 
 4.2.2 Without Good Reason. The Executive may terminate the
Executive’s employment hereunder for other than Good Reason upon thirty (30) days written notice to the Company. 
 4.3
Termination by Mutual Agreement of the Parties. The Executive’s employment pursuant to this Agreement may be terminated at any time upon a mutual agreement in writing of the parties. Any such termination of employment shall have the
consequences specified in such mutual agreement. 
 4.4 Compensation to Executive Upon Termination. In connection with any
termination of the Executive’s employment for any reason, the Executive or the Executive’s estate, as applicable, shall be entitled to any amounts payable to the Executive or the Executive’s beneficiaries subject to and accordance
with the terms of the Company’s employee welfare benefit plans or policies (excluding any severance pay), as well as any other compensation and benefits specified in this Agreement. 

4.4.1 Death or Complete Disability. If the Executive’s employment shall be terminated by his death or Complete Disability
as provided in Section 4.1.1, the Company shall pay to Executive, and/or Executive’s heirs, all earned but unpaid Base Salary earned through the date of termination, any earned but unpaid discretionary Bonuses for any prior period at such
time as bonuses would have been paid if the Executive remained employed, all accrued but unpaid business expenses, and all accrued but unused vacation time earned through the date of termination at the rate in effect at the time of termination
(hereinafter collectively referred to as the “Accrued Amounts”), less standard deductions and withholdings. The Executive shall also be eligible to receive a 

 
pro-rated Bonus for the year in which the date of termination occurs, as determined by the Board or the Compensation Committee of the Board based on
Executive’s then -current target Bonus and based on actual performance and the period of the year he was employed (hereinafter referred to as the “Pro-rata Bonus”), less
standard deductions and withholdings, to be paid as a lump sum within thirty (30) days after the date of termination. 
 4.4.2
With Cause or Without Good Reason. If the Executive’s employment shall be terminated by the Company for Cause, or if the Executive terminates employment hereunder without Good Reason, the Company shall pay the Executive’s Base
Salary earned through the date of termination, his accrued but unpaid business expenses and his accrued and unused vacation benefits earned through the date of termination at the rate in effect at the time of termination, less standard deductions
and withholdings. 
 4.4.3 Without Cause or For Good Reason. 

(i) Not in Connection With a Change in Control. If the Company terminates the Executive’s employment without Cause or the
Executive terminates his employment for Good Reason, and Section 4.4.3(ii) below does not apply, the Company shall pay the Accrued Amounts subject to standard deductions and withholdings, to be paid as a lump sum no later than thirty
(30) days after the date of termination. In addition, subject to the limitations stated in this Agreement and upon the Executive’s furnishing to the Company an executed waiver and release of claims (the form of which is attached hereto as
Exhibit A) (the “Release”) within the applicable time period set forth therein, but in no event later than forty-five days following termination of employment and permitting such Release to become effective in accordance with
its terms (the “Release Effective Date”), and subject to Executive entering into no later than the Release Effective Date a non-competition agreement to be effective during the
Severance Period (as defined below), substantially similar to Section 2.3, and continuing to abide by its terms during the Severance Period, the Executive shall be entitled to: 

(a) the equivalent of the Executive’s Base Salary in effect at the time of termination will continue to be paid for a period of
twelve (12) months following the date of termination (hereinafter referred to as the “Non Change in Control Severance Period”), less standard deductions and withholdings, to be paid
during the Non Change in Control Severance Period according to the Company’s regular payroll practices, subject to any delay in payment required by Section 4.6 in connection with the Release Effective Date; and 

(b) in the event the Executive timely elects continued coverage under COBRA, the Company will continue to pay the same portion of
Executive’s COBRA health insurance premium as the percentage of health insurance premiums that it paid during the Executive’s employment, including any amounts that Company paid for benefits to the qualifying family members of the
Executive, following the date of termination up until the earlier of either (i) the last day of the Non 

 
Change in Control Severance Period or, (ii) the date on which the Executive begins full-time employment with another company or business entity which offers comparable health insurance
coverage to the Executive (such period, the “Non Change in Control COBRA Payment Period”). Notwithstanding the foregoing, if the Company determines, in its sole discretion, that the Company cannot provide the COBRA premium
benefits without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company shall in lieu thereof pay Executive a taxable cash amount,
which payment shall be made regardless of whether the Executive or his qualifying family members elect COBRA continuation coverage (the “Health Care Benefit Payment”). The Health Care Benefit Payment shall be paid in monthly
or bi-weekly installments on the same schedule that the COBRA premiums would otherwise have been paid to the insurer. The Health Care Benefit Payment shall be equal to the amount that the Company otherwise
would have paid for COBRA insurance premiums (which amount shall be calculated based on the premium for the first month of coverage), and shall be paid until the expiration of the Non Change in Control COBRA Payment Period. 

(ii) In Connection With a Change in Control. If the Company (or its successor) terminates the Executive’s employment
without Cause or the Executive terminates his employment for Good Reason within the period commencing three (3) months immediately prior to a Change in Control of the Company and ending eighteen (18) months immediately following a Change
in Control of the Company (as defined in Section 4.5.4 of this Agreement), the Executive shall receive the Accrued Amounts subject to standard deductions and withholdings, to be paid as a lump sum no later than thirty (30) days after the
date of termination. In addition, subject to the limitations stated in this Agreement and upon the Executive’s furnishing to the Company (or its successor) an executed Release within the applicable time period set forth therein, but in no event
later than forty-five days following termination of employment and permitting such Release to become effective in accordance with its terms, and subject to Executive entering into no later than the Release Effective Date a non-competition agreement to be effective during the Severance Period, substantially similar to Section 2.3, and continuing to abide by its terms during the Severance Period, then in lieu of (and not additional
to) the benefits provided pursuant to Section 4.4.3(i) above, the Executive shall be entitled to: 
 (a) the equivalent of the
Executive’s Base Salary in effect at the time of termination will continue to be paid for a period of eighteen (18) months following the date of termination (hereinafter referred to as the “Change in Control Severance
Period”), less standard deductions and withholdings, to be paid during the Change in Control Severance Period according to the Company’s regular payroll practices, subject to any delay in payment required by Section 4.6 in
connection with the Release Effective Date; 
 (b) one and half (1.5) times Executive’s target Bonus in effect at the time of
termination, or if none, one and half (1.5) times the last target 

 
Bonus in effect for Executive, less standard deductions and withholdings, to be paid in a lump sum within ten (10) days following the later of (i) the Release Effective Date, or
(ii) the effective date of the Change in Control; and 
 (c) in the event the Executive timely elects continued coverage under
COBRA, the Company will continue to pay the same portion of Executive’s COBRA health insurance premium as the percentage of health insurance premiums that it paid during the Executive’s employment, including any amounts that Company paid
for benefits to the qualifying family members of the Executive, following the date of termination until the expiration of the Change in Control Severance Period. Notwithstanding the foregoing, if the Company determines, in its sole discretion, that
the Company cannot provide the COBRA premium benefits without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company shall in lieu
thereof pay Executive the Health Care Benefit Payment, which payment shall be made regardless of whether the Executive or his qualifying family members elect COBRA continuation coverage. The Health Care Benefit Payment shall be paid in monthly or bi-weekly installments on the same schedule that the COBRA premiums would otherwise have been paid to the insurer. The Health Care Benefit Payment shall be equal to the amount that the Company otherwise would have
paid for COBRA insurance premiums (which amount shall be calculated based on the premium for the first month of coverage), and shall be paid until the expiration of the Change in Control Severance Period. 

(iii) No Duplication of Benefits. For the avoidance of doubt, in no event will Executive be entitled to benefits under
Section 4.4.3(i) and Section 4.4.3(ii). If Executive commences to receive benefits under Section 4.4.3(i) due to a qualifying termination prior to a Change in Control and thereafter becomes entitled to benefits under
Section 4.4.3(ii), any benefits previously provided to Executive under Section 4.4.3(i) shall offset the benefits to be provided to Executive under Section 4.4.3(ii) and shall be deemed to have been provided to Executive pursuant to
Section 4.4.3(ii). 
 4.4.4 Equity Award Acceleration. 

(i) Not in Connection With a Change in Control. In the event that the Executive’s employment is terminated without Cause
or for Good Reason and Section 4.4.4 (ii) below does not apply, the vesting of any equity awards granted to Executive that vest solely subject to Executive’s continued services to the Company (the “Time-Based Vesting Equity
Awards”) shall be deemed vested and immediately exercisable (if applicable) by the Executive with respect to such number of shares as determined in accordance with their applicable vesting schedules as if Executive had provided an
additional twelve (12) months of services as of the date of termination. Treatment of any performance based vesting equity awards granted to Executive will in all cases be governed solely by the terms of the equity award plan and/or agreement
under which they were granted and will not be eligible to accelerate 

 vesting pursuant to the foregoing provision. 

(ii) In Connection With a Change in Control. In the event that the Executive’s employment is terminated without Cause or
for Good Reason within the three (3) months immediately preceding or during the eighteen (18) months immediately following a Change in Control of the Company (as defined in Section 4.5.4 of this Agreement), the vesting of any
Time-Based Vesting Equity Awards granted to Executive shall be fully accelerated such that on the effective date of such termination (or if later, the date of the Change in Control) one hundred percent (100%) of any Time-Based Vesting Equity Awards
granted to Executive prior to such termination shall be fully vested and immediately exercisable, if applicable, by the Executive. Treatment of any performance based vesting equity awards granted to Executive will in all cases be governed solely by
the terms of the equity award plan and/or agreement under which they were granted and will not be eligible to accelerate vesting pursuant to the foregoing provision. 

(iii) Release and Waiver. Any equity vesting acceleration pursuant to this Section 4.4.4 shall be conditioned upon and
subject to the Executive’s delivery to the Company of a fully effective Release in accordance with the terms specified by Section 4.4.3 hereof and such vesting acceleration benefit shall be in addition to the benefits provided by
Section 4.4.3 hereof. 
 4.5 Definitions. For purposes of this Agreement, the following terms shall have the following
meanings: 
 4.5.1 Complete Disability. “Complete Disability” shall mean the inability of the
Executive to perform the Executive’s duties under this Agreement, whether with or without reasonable accommodation, because the Executive has become permanently disabled within the meaning of any policy of disability income insurance covering
employees of the Company then in force. In the event the Company has no policy of disability income insurance covering employees of the Company in force when the Executive becomes disabled, the term “Complete Disability”
shall mean the inability of the Executive to perform the Executive’s duties under this Agreement, whether with or without reasonable accommodation, by reason of any incapacity, physical or mental, which the Board, based upon medical advice or
an opinion provided by a licensed physician, determines to have incapacitated the Executive from satisfactorily performing all of the Executive’s usual services for the Company, with or without reasonable accommodation, for a period of at least
one hundred eighty (180) days during any twelve (12) month period that need not be consecutive. 
 4.5.2 Good
Reason. “Good Reason” for the Executive to terminate the Executive’s employment hereunder shall mean the occurrence of any of the following events without the Executive’s consent: 

(i) a material reduction in the Executive’s duties, authority, or responsibilities relative to the duties, authority, or
responsibilities in effect immediately 

 
prior to such reduction, including by way of example, having the same title, duties, authority and responsibilities at a subsidiary level following a Change in Control; 

(ii) the relocation of the Executive’s primary work location to a point more than fifty (50) miles from the Executive’s
current work location set forth in Section 1.5 that requires a material increase in Executive’s one-way driving distance; 

(iii) a material reduction by the Company of the Executive’s Base Salary or annual target Bonus opportunity, without the written
consent of the Executive, as initially set forth herein or as the same may be increased from time to time pursuant to this Agreement; and 

(iv) a material breach by the Company of Section 1.2 of this Agreement. 

Provided, however that, such termination by the Executive shall only be deemed for Good Reason pursuant to the foregoing definition if (i) the Company is
given written notice from the Executive within sixty (60) days following the first occurrence of the condition that he considers to constitute Good Reason describing the condition and the Company fails to satisfactorily remedy such condition
within thirty (30) days following such written notice, and (ii) the Executive terminates employment within thirty (30) days following the end of the period within which the Company was entitled to remedy the condition constituting
Good Reason but failed to do so. 
 4.5.3 Cause. “Cause” for the Company to terminate Executive’s
employment hereunder shall mean the occurrence of any of the following events, as determined reasonably and in good faith by the Board or a committee designated by the Board: 

(i) the Executive’s gross negligence or willful failure to substantially perform his duties and responsibilities to the Company
or willful and deliberate violation of a Company policy; 
 (ii) the Executive’s conviction of a felony or the Executive’s
commission of any act of fraud, embezzlement or dishonesty against the Company or involving moral turpitude that is likely to inflict or has inflicted material injury on the business of the Company, to be determined by the sole discretion of the
Company; 
 (iii) the Executive’s unauthorized use or disclosure of any proprietary information or trade secrets of the Company
or any other party that the Executive owes an obligation of nondisclosure as a result of the Executive’s relationship with the Company; and 

(iv) the Executive’s willful and deliberate breach of the obligations under this Agreement that causes material injury to the
business of the Company. 

 4.5.4 Change in Control. For purposes of this Agreement, “Change in
Control” means: (i) a sale of all or substantially all of the assets of the Company; (ii) a merger or consolidation in which the Company is not the surviving entity and in which the holders of the Company’s outstanding
voting stock immediately prior to such transaction own, immediately after such transaction, securities representing less than fifty percent (50%) of the voting power of the entity surviving such transaction or, where the surviving entity is a
wholly-owned subsidiary of another entity, the surviving entity’s parent; (iii) a reverse merger in which the Company is the surviving entity but the shares of Common Stock outstanding immediately preceding the merger are converted by
virtue of the merger into other property, whether in the form of securities of the surviving entity’s parent, cash or otherwise, and in which the holders of the Company’s outstanding voting stock immediately prior to such transaction own,
immediately after such transaction, securities representing less than fifty percent (50%) of the voting power of the Company or, where the Company is a wholly-owned subsidiary of another entity, the Company’s parent; or (iv) an acquisition
by any person, entity or group (excluding any employee benefit plan, or related trust, sponsored or maintained by the Company or subsidiary of the Company or other entity controlled by the Company) of the beneficial ownership of securities of the
Company representing at least seventy-five percent (75%) of the combined voting power entitled to vote in the election of Directors; provided, however, that nothing in this paragraph shall apply to a sale of assets, merger or other transaction
effected exclusively for the purpose of changing the domicile of the Company. 
 4.6 Application of Internal Revenue Code
Section 409A. Notwithstanding anything to the contrary set forth herein, any payments and benefits provided under this Agreement (the “Severance Benefits”) that constitute
“deferred compensation” within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), and the regulations and other guidance thereunder and any state law of similar
effect (collectively “Section 409A”), shall not commence in connection with Executive’s termination of employment unless and until Executive has also incurred a “separation from
service” (as such term is defined in Treasury Regulation Section 1.409A-1(h) (“Separation From Service”), unless the Company reasonably determines that such amounts may be
provided to Executive without causing Executive to incur the additional 20% tax under Section 409A. 
 It is intended that each
installment of the Severance Benefits payments provided for in this Agreement is a separate “payment” for purposes of Treasury Regulation Section 1.409A-2(b)(2)(i). For the avoidance of doubt,
it is intended that payments of the Severance Benefits set forth in this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Section 409A provided under Treasury Regulation Sections 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9). However, if the Company (or, if applicable, the successor entity thereto) determines
that the Severance Benefits constitute “deferred compensation” under Section 409A and Executive is, on the termination of service, a “specified employee” of the Company or any successor entity thereto, as such term is
defined in Section 409A(a)(2)(B)(i) of the Code, then, solely to the extent necessary to avoid the incurrence of the adverse personal tax consequences 

 
under Section 409A, the timing of the Severance Benefit payments shall be delayed until the earlier to occur of: (i) the date that is six months and one day after Executive’s
Separation From Service, or (ii) the date of Executive’s death (such applicable date, the “Specified Employee Initial Payment Date”), the Company (or the successor entity thereto, as applicable) shall (A) pay
to Executive a lump sum amount equal to the sum of the Severance Benefit payments that Executive would otherwise have received through the Specified Employee Initial Payment Date if the commencement of the payment of the Severance Benefits had not
been so delayed pursuant to this Section and (B) commence paying the balance of the Severance Benefits in accordance with the applicable payment schedules set forth in this Agreement. 

Notwithstanding anything to the contrary set forth herein, Executive shall receive the Severance Benefits described above, if and only if
Executive duly executes and returns to the Company within the applicable time period set forth therein, but in no event more than forty-five days following Separation From Service, the Company’s standard form of release of claims in favor of
the Company (attached to this Agreement as Exhibit A) (the “Release”) and permits the release of claims contained therein to become effective in accordance with its terms (such latest permitted date, the “Release
Deadline”). If the severance benefits are not covered by one or more exemptions from the application of Section 409A and the Release could become effective in the calendar year following the calendar year in which Executive
separates from service, the Release will not be deemed effective any earlier than the Release Deadline. Notwithstanding any other payment schedule set forth in this Agreement, none of the Severance Benefits will be paid or otherwise delivered prior
to the effective date (or deemed effective date) of the Release. Except to the extent that payments may be delayed until the Specified Employee Initial Payment Date pursuant to the preceding paragraph, on the first regular payroll pay day following
the effective date of the Release, the Company will pay Executive the Severance Benefits Executive would otherwise have received under the Agreement on or prior to such date but for the delay in payment related to the effectiveness of the Release,
with the balance of the Severance Benefits being paid as originally scheduled. 
 The severance benefits are intended to qualify for an
exemption from application of Section 409A or comply with its requirements to the extent necessary to avoid adverse personal tax consequences under Section 409A, and any ambiguities herein shall be interpreted accordingly. 

4.7 Application of Internal Revenue Code Section 280G. If any payment or benefit Executive would receive
pursuant to a Change in Control from the Company or otherwise (“Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the Code, and (ii) but for this
sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then such Payment shall be equal to the Reduced Amount. The “Reduced Amount” shall be either (x) the largest
portion of the Payment that would result in no portion of the Payment being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount, after taking into account all applicable federal,
state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest 

 
applicable marginal rate), results in Executive’s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some
portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting “parachute payments” is necessary so that the Payment equals the Reduced Amount, reduction shall occur in the manner that results
in the greatest economic benefit for Executive. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata. 

In the event it is subsequently determined by the Internal Revenue Service that some portion of the Reduced Amount as determined pursuant to
clause (x) in the preceding paragraph is subject to the Excise Tax, Executive agrees to promptly return to the Company a sufficient amount of the Payment so that no portion of the Reduced Amount is subject to the Excise Tax. For the avoidance
of doubt, if the Reduced Amount is determined pursuant to clause (y) in the preceding paragraph, Executive will have no obligation to return any portion of the Payment pursuant to the preceding sentence. 

Unless Executive and the Company agree on an alternative accounting firm, the accounting firm engaged by the Company for general tax
compliance purposes as of the day prior to the effective date of the Change in Control shall perform the foregoing calculations. If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group
effecting the Change in Control, the Company shall appoint a nationally recognized accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such accounting firm required
to be made hereunder. 
 The Company shall use commercially reasonable efforts to cause the accounting firm engaged to make the
determinations hereunder to provide its calculations, together with detailed supporting documentation, to Executive and the Company within fifteen (15) calendar days after the date on which Executive’s right to a Payment is triggered (if
requested at that time by Executive or the Company) or such other time as requested by Executive or the Company. 
 4.8
Indemnification Agreements. The Company and the Executive have previously entered into indemnification agreements, copies of which are attached hereto as Exhibit B-1 and Exhibit B-2. 
 4.9 Confidential Information and Invention Assignment Agreement. The Executive has
previously executed the Company’s Confidential Information and Invention Assignment Agreement the terms of which shall continue to govern the terms of Executive’s employment following the Effective Date, and a copy of which is attached as
Exhibit C. 
 4.10 No Mitigation or Offset. The Executive shall not be required to seek or accept other employment, or
otherwise to mitigate damages, as a condition to receipt of the Severance Benefits, and the Severance Benefits shall not be offset by any amounts received by the Executive from any other source, except to the extent that the Executive’s rights
to the benefits described in Sections 4.4.3(i)(b) or 4.4.3(ii)(c), as applicable, are 

 
terminated by reason of the Executive obtaining full-time employment with another company or business entity which offers comparable health insurance coverage. 

 

	5.	 Assignment and Binding Effect. 

This Agreement shall be binding upon the Executive and the Company and inure to the benefit of the Executive and the Executive’s heirs,
executors, personal representatives, assigns, administrators and legal representatives. Because of the unique and personal nature of the Executive’s duties under this Agreement, neither this Agreement nor obligations under this Agreement shall
be assignable by the Executive. This Agreement shall be binding upon and inure to the benefit of the Company and its successors, assigns and legal representatives, provided that the Agreement may only be assigned to an acquirer of all or
substantially all of the Company’s assets. Any such successor of the Company will be deemed substituted for the Company under the terms of this Agreement for all purposes. For this purpose, “successor” means any person, firm,
corporation or other business entity which at any time, whether by purchase, merger or otherwise, directly or indirectly acquires all or substantially all of the assets or business of the Company. 

 

	6.	 Notice. 

For the purposes of this Agreement, notices, demands, and all other forms of communication provided for in this Agreement shall be in writing
and shall be deemed to have been duly given when delivered or (unless otherwise specified) mailed by registered mail, return receipt requested, postage prepaid, or by confirmed facsimile, addressed as set forth below, or to such other address as any
party may have furnished to the other in writing in accordance herewith, except that notices of address shall be effective only upon receipt, as follows: 
  

			
		 	If to the Company:
		
	  
	 	Horizon Pharma, Inc.
		 	150 S. Saunders Road,
		 	Lake Forest, IL 60045
	                        	 	Attention: Timothy P. Walbert, Chairman, President & CEO
		 	Fax: 847-572-1372
		
		 	If to the Executive:
		
		 	Geoff Curtis
		 	                                     
   
		 	                                     
   

 Any such written notice shall be deemed given on the earlier of the date on which such notice is personally delivered or five
(5) days after its deposit in the United States mail as specified above. Either party may change its address for notices by giving written notice to the other party in the manner specified in this section. 

	7.	 Choice of Law. 

This Agreement shall be governed by the laws of the State of Illinois, without regard to any conflicts of law principals thereof that would
call for the application of the laws of any other jurisdiction. The parties consent to the exclusive jurisdiction and venue of the federal court in the Northern District of Illinois, and state courts located in the state of Illinois, county of Cook.
Nothing in this Section 7 limits the rights of the parties to seek appeal of a decision of an Illinois court outside of Illinois that has proper jurisdiction over the decision of a court sitting in Illinois. 

 

	8.	 Integration. 

This Agreement, including Exhibit A, Exhibit B-1, Exhibit B-2
and Exhibit C contains the complete, final and exclusive agreement of the parties relating to the terms and conditions of the Executive’s employment and the termination of Executive’s employment, and supersedes all prior and
contemporaneous oral and written employment agreements or arrangements between the parties, including but not limited to the Prior Agreement. 
  

	9.	 Amendment. 

This Agreement cannot be amended or modified except by a written agreement signed by the Executive and the Company. 

 

	10.	 Waiver. 

No term, covenant or condition of this Agreement or any breach thereof shall be deemed waived, except with the written consent of the party
against whom the wavier is claimed, and any waiver or any such term, covenant, condition or breach shall not be deemed to be a waiver of any preceding or succeeding breach of the same or any other term, covenant, condition or breach. 

 

	11.	 Severability. 

The finding by a court of competent jurisdiction of the unenforceability, invalidity or illegality of any provision of this Agreement shall not
render any other provision of this Agreement unenforceable, invalid or illegal. Such court shall have the authority to modify or replace the invalid or unenforceable term or provision with a valid and enforceable term or provision, which most
accurately represents the parties’ intention with respect to the invalid, unenforceable, or illegal term or provision. 
  

	12.	 Interpretation; Construction. 

The headings set forth in this Agreement are for convenience of reference only and shall not be used in interpreting this Agreement. This
Agreement has been drafted and negotiated by legal counsel representing the Company and the Executive. The parties acknowledge that each party and its counsel has reviewed and revised, or had an opportunity to review and revise, this Agreement, and
any rule of construction to the 

 
effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Agreement. 

 

	13.	 Execution by Facsimile Signatures and in Counterparts. 

The parties agree that facsimile signatures shall have the same force and effect as original signatures. This Agreement may be executed in one
or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument. 
  

	14.	 Survival. 

The provisions of this Agreement, and of all other agreements referenced herein, shall survive the termination of this Agreement, and of the
Executive’s employment by the Company for any reason, to the extent necessary to enable the parties to enforce their respective rights hereunder. 

[Remainder of Page Intentionally Left Blank] 

 IN WITNESS WHEREFORE, the parties have signed this Agreement on the date first
written above. 
  

	
	COMPANY:
	
	 HORIZON PHARMA, INC.
 HORIZON PHARMA
USA, INC.

	
	By:
	
	Title: Chairman, President & CEO
	
	Print Name: Timothy P. Wa1bert
	
	 /s/ Timothy P. Walbert

	Signature
	
	 As authorized agent of the Company

	
	     11/5/18

	Date
	
	EXECUTIVE:
	
	 /s/ Geoff Curtis

	Geoff Curtis, individually
	
	     11/5/18

	DateExhibit

                                                
Exhibit 10.36

Note: Information has been omitted from this agreement pursuant to a request for confidential treatment, and such information has been separately filed with the Securities and Exchange Commission. The omitted information has been marked with a bracketed asterisk (“[*]”).

November 12, 2018

Megan Molony
National Vision, Inc.
2435 Commerce Ave.
Building 2200
Duluth, GA 30096
Megan.Molony@nationalvision.com

Via Electronic Mail
                                    
Dear Ms. Molony:

This Letter Agreement and the attached Schedules (collectively, the “Agreement”) reflect the terms and conditions agreed upon by and among National Vision, Inc. (“Customer”) and Essilor of America, Inc., on behalf of itself or one of its affiliates (collectively, “Essilor”), regarding Customer’s purchase from Essilor of ophthalmic lenses and certain licensed products from Essilor during the Term (as defined below in Section 4 of this Agreement).  If Customer agrees with all of the terms and conditions set forth herein, it should sign and execute this Agreement in the signature blocks set forth below.  

		
	1.
	Background

Essilor is a leading manufacturer of lens products and operates a network of optical laboratories.  Customer currently operates  a diverse portfolio of 1,067 retail stores across five retail brands as of September 29, 2018, under the banners “America’s Best Contacts & Eyeglasses,” “Eyeglass World,” “Vista Optical,” and “The Vision Center brought to you by Walmart” (the “Retail Stores”), and several e-commerce websites, including “AC Lens”.  For purposes of the exclusivity provisions of this Agreement, the term “Retail Stores” shall include any new Retail Stores added by Customer during the Term under the above-referenced banners (up to 75 locations per year) with the exception of those retail stores operating under the banner “The Vision Center brought to you by Walmart.” 

		
	2.
	Direct Lenses    

On behalf of its Retail Stores, Customer wishes to purchase from Essilor, and Essilor, in turn, wishes to provide to Customer on an exclusive basis, the categories of ophthalmic lenses listed on Schedule A (the “Direct Lenses”), unless otherwise mutually agreed upon by the parties.  To avoid confusion, unless otherwise mutually agreed upon by the parties, Customer agrees to purchase the categories of Direct Lenses listed on Schedule A exclusively from Essilor, with the exception of specialty sun lenses; Essilor, however, will be free to provide Direct Lenses to other customers.  

In the event Customer elects to offer a new product category to its customers not included on Schedule A or the License Agreements (as defined herein), Customer agrees to provide Essilor with a right of first refusal to provide such product category.  Customer will provide Essilor with a right of first refusal notice (the “Notice”) that will specify Customer’s reasonable product needs, technical, laboratory, delivery and any other requirements with respect to the new product 

category; provided that Essilor will be given a period of at least three (3) months with respect to the initial delivery of the product. The parties will agree upon a reasonable timeline for Essilor to respond to the Notice (such time not to exceed thirty days).  Essilor shall have the opportunity to respond to the Notice by submitting an offer to Customer to provide a comparable product at a competitive price. If Essilor does not respond to the Notice by the agreed upon deadline or is unable to reasonably meet the Customer’s specified, requirements as set forth in the Notice, which shall be reasonably measured by Customer based on technical requirements, quality of laboratory operations impact and cost, Customer shall have the right to source the new product category from a third party other than Essilor. The parties agree that if there is a question or dispute regarding whether a product constitutes an existing product category covered under Schedule A ̧ or is  a new product category subject to this right of first refusal provision, and the parties cannot resolve such question or dispute after working in good faith, the right of first refusal provisions of this paragraph shall apply.

The parties agree that, except as provided herein, Essilor will not sell lenses directly to Customer’s Hong Kong partner laboratory (“HKO”) or Mexico partner laboratory (“OMX”) under this Agreement to be processed by HKO or OMX so that they will, in effect, be purchased by and billed to Customer. Notwithstanding the foregoing, Essilor will reasonably consider alternative arrangements for the supply by Essilor of lenses to HKO and OMX, which alternative arrangements may include the direct supply by Essilor of lenses to HKO and OMX. 

Notwithstanding the foregoing, Customer agrees that the Direct Lenses supplied by Essilor pursuant to this Agreement shall be utilized solely for resale in Customer’s retail establishments and shall not be resold in a wholesale context.  

		
	3.
	Technology Agreements

The parties acknowledge that arrangements with respect to Customer’s access digital surfacing and lens coating technology shall be governed by the Digital Surfacing License Agreement and the Agreement Regarding Lens Coating (collectively, the “License Agreements”) entered into between the parties.  

		
	4.
	Term and Termination

(a)    Term.  The term of this Agreement shall extend from June 1, 2019, until May 31, 2023 (the “Initial Term”), unless terminated earlier (or extended) pursuant to the terms of this Agreement.  Thereafter, this Agreement shall automatically renew on a month-to-month basis (collectively the “Renewal Term”), unless either party gives the other at least thirty (30) days’ prior written notice of the end of the Initial Term or Renewal Term, as applicable, of its desire to terminate the Agreement.  Notwithstanding the foregoing, Customer shall have the ability to unilaterally extend this Agreement an additional calendar quarter after the proposed termination date. Each one (1) year anniversary of this Agreement shall be referred to as a “Contract Year.”  By way of example, Contract Year 1 shall extend from June 1, 2019 until May 31, 2020.

(b)    Termination.  (i) In addition to all other remedies provided by law or specified in this Agreement, each of Customer and Essilor (the “Non-Breaching Party”) may immediately terminate this Agreement by providing notice of such termination to the other party (the “Breaching Party”) upon the occurrence of any of the following events:
	
					
	Confidential treatment has been requested with respect to information contained within the [*] marking. Such portions have been omitted from this filing and have been separately filed with the Securities and Exchange Commission.

a.    The insolvency of, filing of a petition in bankruptcy by, against, or on behalf of, or appointment of a receiver or trustee for all or substantially all of the property of, the Breaching Party; or any dissolution, liquidation, or other insolvency proceeding by, against, or on behalf of the Breaching Party; or

b.    Breaching Party’s material breach of or material failure to perform any of the terms, conditions, or covenants contained in this Agreement that is not corrected within thirty (30) days after receipt of notice of such breach; provided, however, if the breach is not capable of being cured within such thirty (30) day period 

and the Breaching Party is diligently pursuing such a cure, the Breaching Party shall not be deemed to be in default.  In no event shall such cure period exceed sixty (60) days.

(ii)    In addition to all other remedies provided by law or specified in this Agreement, and at the request of NVI in light of the recent combination of Essilor International SA and Luxottica Group, all exclusivity provisions of this Agreement shall terminate and/or Customer may terminate this Agreement by providing at least thirty (30) days’ notice to Essilor upon the occurrence of any of the following events:

a.    If an amendment or extension to the EyeMed Vision Care Eye Care Professional Agreement between EyeMed Vision Care, LLC (“EyeMed”) and NVI (the “EyeMed Agreement”) is not executed prior to December 31, 2018; or

b.    If (1) EyeMed terminates the EyeMed Agreement, or (2) EyeMed materially changes the terms of the EyeMed Agreement in a way that negatively impacts NVI or any of its Brands (as defined in the EyeMed Agreement) that results in termination of the EyeMed Agreement, or (3) causes NVI or any of its Brands (as defined in the EyeMed Agreement) to no longer be eligible to provide in-network services under the EyeMed Agreement, provided that the foregoing shall not apply to a termination due to a material breach of the EyeMed Agreement by NVI.

(c)    Effect of Termination.  Upon a termination of this Agreement, the following amounts shall become fully and automatically due, owing, and payable within (10) days after the effective date of termination: (1) any account balances, (2) any other amounts that Customer owes to Essilor under this Agreement and (3) all amounts that Essilor owes to Customer under this Agreement pursuant to Section 10 through the effective date of termination.  In such event, the parties agree to waive any and all rights to offset. 

		
	5.
	Pricing

During the Term, Customer shall compensate Essilor for the Direct Lenses in accordance with prices set forth in the attached Schedule A.  

		
	6.
	Payment Terms

[*]

		
	7.
	Shipping and Freight 

The parties agree that shipments by Essilor to HKO and OMX will be either to (i) the addresses set forth on Schedule B for the respective facilities, (ii) other addresses for HKO and OMX within their current shipping jurisdictions, upon the reasonable discussion between the parties regarding the technicalities and terms related to shipping to such addresses, or (iii) to such other addresses as mutually agreed between the parties.

Other than as described below with respect to lenses processed by an Essilor laboratory, Essilor will be responsible for all freight and other charges including duties on shipments to Customer’s U.S. and OMX production facilities. Customer will be responsible for all freight and other charges including duties on shipments to HKO.  Shipping method will be ground freight for stock replenishment orders and 2-Day freight to domestic labs.  Customer agrees to cover actual shipping costs for all shipments of lenses processed by an Essilor laboratory that are then shipped to Customer from such laboratory.  Other than with respect to shipments to HKO, which will be shipped Exworks, title for all shipments will pass and Customer will assume all risk of loss of product at the time of delivery, which will be F.O.B. point of delivery. Except as described above, Essilor shall ship lenses in accordance with practices and timeframes currently in effect for domestic shipments by Essilor to Customer.

		
	8.
	Defect Rates 

[*]

		
	9.
	Forecasting Information 

Customer and Essilor agree to meet quarterly to review Customer’s upcoming planned promotions, sales initiatives, planned new store openings, and seasonality trends as they may impact Essilor’s supply chain forecasting.

		
	10.
	Loyalty and Transitions® Lens Rebates

[*]

		
	11.
	Inspection and Audit

    
Customer shall keep accurate and complete registers which shall record the exact number of Direct Lenses purchased under this Agreement and any other information needed to determine its compliance with the requirements of this Agreement.

Upon reasonable belief that Customer is not in compliance with the exclusivity provisions of this Agreement, Essilor shall have the right to appoint an accountant and, at a mutually agreeable time, inspect NVI’s registers for the sole purpose of determining Customer’s compliance with the terms of this Agreement.

The costs of such inspection and examination shall be borne by Essilor. They shall, however, be reimbursed by Customer to the extent the audit results in a finding that Customer has failed to fully comply with the exclusivity provisions of this Agreement.

		
	12.
	Rebate Reports

Within ninety (90) days of the end of each Contract Year, Essilor shall send Customer a written “Rebate Report” detailing:

		
	•
	The amount of Customer's Direct Lens purchases and License Fees in the just concluded Contract Year;

		
	•
	The annual Performance Rebate and Transitions Rebate that Customer earned pursuant to the terms and conditions of the Agreement in the just concluded Contract Year; and

		
	•
	The type, quantity, and dollar amounts of Customer’s Direct Lens purchases and License Fees paid to Essilor for the just concluded Contract Year; and

		
	•
	Other rebates or discounts, if any, received by Customer.   

		
	13.
	Compliance with Terms and Law

Each of the parties to this Agreement agrees to comply with (1) the terms and conditions of this Agreement and (2) all applicable laws and regulations during the Term.

		
	14.
	Price Transparency

Customer understands and acknowledges that Customer may be requested-pursuant to applicable laws, regulations or contractual provisions-to fully and accurately report and disclose all price reductions (e.g., discounts and rebates) received by Essilor under this Agreement, which such information shall be contained in the Rebate Reports provided under this Agreement.  Customer covenants and agrees that it shall (1) comply with its reporting and disclosure requirements, if any, and (2) provide the relevant governmental authority, health care plan or program, or third party payer with such other information about the price reductions it received, upon request.

Customer may wish to consult with its legal advisers regarding how, where, and when any price reductions received under this Agreement should be reported and otherwise disclosed, including whether and how such price reductions should be apportioned over Customer's purchases during the relevant Contract Year. 

		
	15.
	Representations and Warranties

Each party represents and warrants to the other that on and as of the date of this Agreement, each and every representation and warranty set forth is true and accurate.

Each party has full corporate power and authority to execute, deliver and perform the obligations contemplated by this Agreement and this Agreement and the transactions contemplated hereby have been duly and validly authorized by all necessary corporate action on the part of such party.

This Agreement, as executed and delivered, constitutes legal, valid and binding obligations of each party enforceable in accordance with its terms.  The execution, delivery and performance of this Agreement does not violate or contravene any provision of law, or conflict with the Articles of Incorporation of either party or any other document or charter under which such party was established, or conflict with or result in the breach of any provision of any agreement to which such party is a party, or constitute a default or an event that, with the giving of notice, or the passing of time, would create such a default.

Essilor represents and warrants that (a) it possesses all federal, state and local licenses and permits necessary to manufacture and sell the products in accordance with the terms of this Agreement, (b) the products manufactured by Essilor will be in accordance with legal and industry specifications (including ANSI standards) and will be free from defects in workmanship and material, and (c) Essilor shall comply with all federal, state and local laws and regulations applicable to the manufacture and sale of the products in accordance with the terms of this Agreement.

		
	16.
	Force Majeure

In the event either party is prevented or delayed in the performance of any obligation required under this Agreement due to delays caused by fire, catastrophe, strikes or labor trouble, civil commotion, acts of God, governmental prohibitions or regulation, inability or difficulty to obtain materials or other causes beyond the performing party's reasonable control, the performing party shall, within ten (10) days of the event causing such delay, provide written notice to the other party of the event causing the delay and the anticipated period of delay, and the period of such delay shall be added to the time for performance thereof.   The performing party shall have no liability by reason of such permitted delays. In the event the performing party fails to provide notice to the other party of the force majeure delay within such ten (10) day period, the performing party shall not be excused from the timely performance of such obligation regardless of the cause. Notwithstanding the foregoing, Customer shall have the right, in the event of a force majeure delay that adversely affects the ability of Essilor to timely deliver the Direct Lenses under this Agreement, to order any Direct Lenses from a source other than Essilor. 

		
	17.
	Confidentiality

The contents of this Agreement and confidential information exchanged in connection therewith are deemed confidential, shall not be disclosed to third parties, and shall be treated under an existing non-disclosure agreement between the parties.  Notwithstanding the foregoing, each party may disclose such matters (a) in connection with tax proceedings, arbitration,  or litigation that involves the terms of this Agreement and (b) to (i) its officers, directors, affiliates, employees, accountants, attorneys, advisors, and other individuals who need to know such contents in connection with their duties on behalf of such party; (ii) actual or potential financing sources, and other parties that may enter into business transactions with each party or its affiliates (including any Contract Laboratories, hereafter defined); and (iii) government authorities (including courts and administrative agencies) if required by or advisable under applicable legal requirements. The foregoing shall not prevent either party from disclosing the existence of their vendor/customer arrangement.

		
	18.
	Confidentiality of Price List as to HKO and Mexico Laboratory

The parties acknowledge that Essilor considers the Price List confidential and that Customer intends to contract with HKO and laboratories in Mexico, and may in the future contract with other laboratories not owned or under common control with Customer (all the foregoing, “Contract Laboratories”) to process certain of the Direct Lenses for Customer. The parties accordingly agree that Customer will not contract with a Contract Laboratory for the processing of Direct Lenses unless and until either (a) the Contract Laboratory has entered into a customary confidentiality agreement, in a form and on terms substantially the same as that attached hereto as Schedule C, pursuant to which the Contract Laboratory has agreed to keep confidential the terms of the Price List or (b) Essilor and Customer have agreed upon procedures to enable the Contract Laboratory to process the Direct Lenses without having access to such terms (such procedure may include the direct shipment of the Direct Lenses to the Contract Laboratory). Essilor and Customer agree to work reasonably together to agree upon such procedures.

		
	19.
	Relationships of the Parties

For purposes of the Agreement and the transactions provided for herein, the parties to the Agreement shall be deemed to be independent contractors.  Nothing in the Agreement is intended to create, nor shall it be construed to create, an employer-employee, franchisor-franchisee, joint venture or partnership relationship between the parties.

		
	20.
	Indemnification, Warranties and Limitation of Remedy and Liabilities

Each party, on behalf of its respective successors, heirs and assigns, agrees to protect, defend, hold harmless and indemnify the other party, its respective parent, subsidiaries and affiliated corporations, as well as their directors, officers and employees, from and against any and all expenses, claims (including third party claims), actions, liabilities, losses and damages of any kind whatsoever (including, without limitation of the foregoing, death or injury to persons) resulting or arising out of the performance of or failure of the indemnifying party, its respective agents, employees or permitted assignees, to perform any of their joint or respective obligations pursuant to the terms of the Agreement or from any misrepresentation or the omission or commission of any act, lawful or unlawful, by the indemnifying party or any of its agents, employees or permitted assignees.

EXCEPT AS PROVIDED FOR HEREIN, ESSILOR HEREBY DISCLAIMS ALL WARRANTIES, REPRESENTATIONS AND CONDITIONS, STATUTORY OR OTHERWISE, EXPRESS OR IMPLIED, OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.  THE SOLE AND EXCLUSIVE REMEDY AVAILABLE TO SHALL BE AS PROVIDED IN THIS AGREEMENT.  IN NO EVENT WILL EITHER PARTY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES ON ANY LEGAL THEORY, WHETHER IN CONTRACT, TORT, EQUITY, OR AT LAW, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

		
	21.
	Arbitration  

Any controversy, dispute or claim arising out of the interpretation, performance or breach of the Agreement shall be resolved by binding arbitration at the request of either party, in accordance with the Commercial Arbitration Rules of the American Arbitration Association.  The arbitrators shall apply New York substantive law and federal substantive law where state law is preempted.  Civil discovery for use in such arbitration may be conducted in accordance with the provisions of New York law, and the arbitrator(s) selected shall have the power to enforce the rights, remedies, duties, liabilities and obligations of discovery by the imposition of the same terms, conditions and penalties as can be imposed in like circumstances in a civil action by a court of competent jurisdiction of the State of New York.  The provisions of New York law concerning the right to discovery and the use of depositions in arbitration are incorporated herein by reference and made applicable to the Agreement.  The arbitrators shall have the power to grant all legal and equitable remedies and award compensatory damages provided by New York law, subject to the limitations on damages set forth above.  The arbitrators shall prepare in writing and provide to the parties an award including factual findings and the legal reasons on which the award is based.  The arbitrators shall not have the power to commit errors of law or legal reasoning.  Notwithstanding the above, in the event any party wishes to obtain injunctive relief or a temporary restraining order, such party may initiate an action for such relief in 

any court of competent jurisdiction.  However, the courts shall not have the authority to review or grant any request or demand for damages.

		
	22.
	Attorneys’ Fees; Interest  

In the event that either party to the Agreement institutes litigation or arbitration against the other party to enforce any of the terms or conditions of the Agreement, the prevailing party in such litigation or arbitration shall be entitled to recover reasonable costs and attorneys’ fees incurred by it from the other party.  If any monthly statements are not timely paid by Customer, such obligation shall accrue interest at the lower of the highest interest rate allowed by applicable law and one and one-half percent (1 1⁄2%) per month from the date that each such obligation is due until paid.

		
	23.
	Waiver 

The failure of either party to seek redress for violation of, or to insist upon strict performance of, any term, covenant or condition contained in the Agreement shall not prevent a similar subsequent act from constituting a default under the Agreement.

14.    Previous Agreements, Modifications, and Assignment  

This Agreement replaces any other preceding agreement, whether written or oral, between the parties on the subject matter hereof.  The parties acknowledge that certain Direct Lens Supply Letter Agreement, dated May 25, 2011, as amended (the “Original Agreement”) shall remain in effect until the commencement of the Initial Term under this Agreement.  No addition or modification to this Agreement shall be valid unless made in writing signed by both parties hereto.  If any provision or clause of this Agreement is found to be null and void or unenforceable, the balance of this Agreement will be construed as a whole to effect as closely as practicable the original intent of the parties.  Neither party may assign any of its rights or obligations under this Agreement to any other party without the prior written consent of the other, except for a transfer to an entity controlled by or under common control with the assigning party.  Each and every assignee of any right(s) or obligation(s) under this Agreement shall be bound by all of the terms and conditions hereof.

		
	24.
	Notice  

Any notices required or permitted to be given hereunder or under the Agreement shall be given in writing and shall be delivered (i) in person, (ii) by certified mail, postage prepaid, return receipt requested, (iii) by facsimile, or (iv) by a commercial overnight courier that guarantees next day delivery and provides a receipt, and such notices shall be addressed as follows:

Essilor:        Essilor of America, Inc.
Office of the General Counsel
13555 N. Stemmons Freeway
Dallas, Texas 75234
Facsimile: (972) 241-1162

Customer:    National Vision, Inc.
2435 Commerce Ave., Building 2200
Duluth, GA 30096
Attn:  General Counsel
With a copy to: Megan Molony 

or to such other address as either party may from time to time specify in writing to the other party.  Any notice shall be effective only upon delivery, which for any notice given by facsimile shall mean notice that has been received by the party to whom it is sent as evidenced by confirmation slip.

		
	25.
	Counterparts; Facsimiles

This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall be deemed to be one and the same instrument.  A signature sent by telecopy or facsimile transmission shall be as valid and binding upon the party as an original signature of such party.

Very truly yours,

ESSILOR OF AMERICA, INC.

	
	
	/s/ Steve Nussbaumer

	Name: Steve Nussbaumer
Title: SVP and General Manager, Key Accounts

By executing below, the undersigned hereby represents and warrants that he/she has the authority to execute this Agreement on behalf of Customer, as applicable, and in furtherance of this Agreement.

AGREED TO AND ACCEPTED BY:

CUSTOMER:

National Vision, Inc.

	
	
	/s/ Megan Molony

	Name: Megan Molony
Title: Sr. Vice President, Merchandising

Date: November 12, 2018

	
					
	Confidential treatment has been requested with respect to information contained within the [*] marking. Such portions have been omitted from this filing and have been separately filed with the Securities and Exchange Commission.

 

Schedule A

[*]†

	
					
	† A four-page schedule, for which confidential treatment has been requested, has been omitted. All such omitted material has been separately filed.

Schedule B

Laboratorio Optimex, S.A. de C.V.
Eugenio Cuzin #945 Parque Industrial Belenes Norte
Zapopan, Jal. Mexico 45150

Hong Kong Optical, LLC.
Flat 03, 10/F, Kwong Sang Hong Centre
151 Hoi Bun Rd, Kwun Tong, Kowloon, Hong Kong

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00292-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00292-of-00352.parquet"}]]